HeartSciences PE Ratio 2022-2025 | HSCS
Current and historical p/e ratio for HeartSciences (HSCS) from 2022 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. HeartSciences PE ratio as of June 20, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| HeartSciences PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-20 | 3.76 | 0.00 | |
| 2025-01-31 | 3.23 | $-7.48 | 0.00 |
| 2024-10-31 | 2.94 | $-7.91 | 0.00 |
| 2024-07-31 | 3.85 | $-21.64 | 0.00 |
| 2024-04-30 | 9.24 | $-32.00 | 0.00 |
| 2024-01-31 | 14.98 | $-48.00 | 0.00 |
| 2023-10-31 | 24.92 | $-61.00 | 0.00 |
| 2023-07-31 | 87.24 | $-67.00 | 0.00 |
| 2023-04-30 | 88.75 | $-82.00 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.004B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.769B | 58.23 |
| Hims & Hers Health (HIMS) | United States | $14.374B | 149.35 |
| Tempus AI (TEM) | United States | $11.826B | 0.00 |
| Doximity (DOCS) | United States | $10.774B | 49.88 |
| IRhythm Technologies (IRTC) | United States | $4.653B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.861B | 60.33 |
| Hinge Health (HNGE) | United States | $3.282B | 0.00 |
| Privia Health (PRVA) | United States | $2.664B | 182.08 |
| Enovis (ENOV) | United States | $1.720B | 9.59 |
| Phreesia (PHR) | United States | $1.560B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.537B | 0.00 |
| Schrodinger (SDGR) | United States | $1.501B | 0.00 |
| Azenta (AZTA) | United States | $1.357B | 63.06 |
| 10x Genomics (TXG) | United States | $1.331B | 0.00 |
| Omnicell (OMCL) | United States | $1.313B | 23.17 |
| Evolent Health (EVH) | United States | $1.086B | 92.50 |
| Claritev (CTEV) | United States | $0.657B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.595B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.514B | 0.00 |
| Veradigm (MDRX) | United States | $0.487B | 0.00 |
| Talkspace (TALK) | United States | $0.448B | 134.00 |
| Standard BioTools (LAB) | United States | $0.399B | 0.00 |
| TruBridge (TBRG) | United States | $0.337B | 746.67 |
| Outset Medical (OM) | United States | $0.336B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.263B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.251B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.203B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.156B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.138B | 0.00 |
| CareCloud (CCLD) | United States | $0.106B | 4.03 |
| Pulmonx (LUNG) | United States | $0.105B | 0.00 |
| American Well (AMWL) | United States | $0.105B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.094B | 0.00 |
| 111 (YI) | China | $0.069B | 0.00 |
| HeartBeam (BEAT) | United States | $0.051B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.046B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.045B | 0.00 |
| Zhongchao (ZCMD) | China | $0.037B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.035B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.016B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.012B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |